Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Inflammopharmacology

Open Access 03-01-2025 | Alzheimer's Disease | Review

Drugs repurposing in the experimental models of Alzheimer’s disease

Authors: Sheer A. Joodi, Weam W. Ibrahim, Mahmoud M. Khattab

Published in: Inflammopharmacology

Login to get access

Abstract

The currently approved drugs for Alzheimer’s disease (AD) are only for symptomatic treatment in the early stages of the disease but they could not halt the neurodegeneration, additionally, the safety profile of the recently developed immunotherapy is a big issue. This review aims to explain the importance of the drugs repurposing technique and strategy to develop therapy for AD. We illustrated the biological alterations in the pathophysiology of AD including the amyloid pathology, the Tau pathology, oxidative stress, mitochondrial dysfunction, neuroinflammation, glutamate-mediated excitotoxicity, insulin signaling impairment, wingless-related integration site/β-catenin signaling, and autophagy. Additionally, we demonstrated the different repurposed drugs in the experimental models of AD including the anti-inflammatory, anti-hypertensive, anti-diabetic, antiepileptic, antidepressant and anticancer drugs. Further, we showed the pipeline and FDA approved drugs for AD. The repurposed drugs have a promising therapeutic activity against AD, confirming the value of the drugs repurposing technique to elucidate curative therapy for AD.

Graphical abstract

Literature
Abd Elmaaboud MA, Estfanous RS, Atef A, Kabel AM, Alnemari KA, Naguib TM, Alsufyani SE, Darwish HW, Arab HH (2023) Dapagliflozin/hesperidin combination mitigates lipopolysaccharide-induced Alzheimer’s disease in rats. Pharmaceuticals 16(10):1370PubMedPubMedCentralCrossRef
Abdel-Aal RA, Hussein OA, Elsaady RG, Abdelzaher LA (2021) Celecoxib effect on rivastigmine anti-Alzheimer activity against aluminum chloride-induced neurobehavioral deficits as a rat model of Alzheimer’s disease; novel perspectives for an old drug. J Med Life Sci 3(4):44–82CrossRef
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21(3):383–421PubMedPubMedCentralCrossRef
Alavi MS, Fanoudi S, Hosseini M, Sadeghnia HR (2022) Beneficial effects of levetiracetam in streptozotocin-induced rat model of Alzheimer’s disease. Metab Brain Dis 37(3):689–700PubMedCrossRef
Alluri R, Kilari EK, Pasala PK, Kopalli SR, Koppula S (2023) Repurposing diltiazem for its neuroprotective anti-dementia role against intra-cerebroventricular streptozotocin-induced sporadic Alzheimer’s disease-type rat model. Life 13(8):1688PubMedPubMedCentralCrossRef
Anrather J, Racchumi G, Iadecola C (2006) NF-κB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 281(9):5657–5667PubMedCrossRef
Arab HH, Eid AH, Yahia R, Alsufyani SE, Ashour AM, El-Sheikh AA, Darwish HW, Saad MA, Al-Shorbagy MY, Masoud MA (2023) Targeting autophagy, apoptosis, and SIRT1/Nrf2 axis with topiramate underlies its neuroprotective effect against cadmium-evoked cognitive deficits in rats. Pharmaceuticals 16(9):1214PubMedPubMedCentralCrossRef
Armato U, Chiarini A, Chakravarthy B, Chioffi F, Pacchiana R, Colarusso E, Whitfield JF, Dal Prà I (2013) Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Aβ42 prompted by exogenous fibrillary or soluble Aβ25–35 in human cortical astrocytes and neurons—therapeutic relevance to Alzheimer's disease. Biochimica et Biophys Acta (BBA) Mol Basis Dis 1832(10): 1634–1652
Ashour NH, El-Tanbouly DM, El Sayed NS, Khattab MM (2021) Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, Aβ extrusion transporter ABCB1, and reversal by PKA inhibitor H89. Prog Neuropsychopharmacol Biol Psychiatry 111:110366PubMedCrossRef
Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ (2009) Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 10(1):94–100PubMedCrossRef
Bitner RS (2012) Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer’s disease therapeutics. Biochem Pharmacol 83(6):705–714CrossRef
Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P, Grubeck-Loebenstein B (2000) Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol Dis 7(6):682–689PubMedCrossRef
Butterfield DA, Pocernich CB (2003) The glutamatergic system and Alzheimer’s disease: therapeutic implications. CNS Drugs 17:641–652PubMedCrossRef
Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid β-peptide. Trends Mol Med 7(12):548–554PubMedCrossRef
Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci 89(21):10075–10078PubMedPubMedCentralCrossRef
Cai Z, Chen G, He W, Xiao M, Yan L-J (2015). "Activation of mTOR: a culprit of Alzheimer’s disease?" Neuropsych Dis Treat: 1015–1030
Chadwick W, Mitchell N, Caroll J, Zhou Y, Park S-S, Wang L, Becker KG, Zhang Y, Lehrmann E, Wood WH III (2011) Amitriptyline-mediated cognitive enhancement in aged 3× Tg Alzheimer’s disease mice is associated with neurogenesis and neurotrophic activity. PLoS One 6(6):e21660PubMedPubMedCentralCrossRef
Chen CH, Eastwood S, Hope T, McDonald B, Francis P, Esiri M (2000) Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer’s disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol 26(4):347–355PubMedCrossRef
Chen D, Zhang Y, Zhang M, Chang J, Zeng Z, Kou X, Chen N (2020) Exercise attenuates brain aging by rescuing down-regulated Wnt/β-Catenin signaling in aged rats. Front Aging Neurosci 12:105PubMedPubMedCentralCrossRef
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F (2024) Alzheimer’s disease drug development pipeline: 2024. Alzheimer’s Demen Transl Res Clin Intervent 10(2):e12465CrossRef
Dhull DK, Jindal A, Dhull RK, Aggarwal S, Bhateja D, Padi SS (2012) Neuroprotective effect of cyclooxygenase inhibitors in ICV-STZ induced sporadic Alzheimer’s disease in rats. J Mol Neurosci 46:223–235PubMedCrossRef
Di Domenico F, Perluigi M, Butterfield D, Cornelius C, Calabrese V (2010) Oxidative damage in rat brain during aging: interplay between energy and metabolic key target proteins. Neurochem Res 35:2184–2192PubMedCrossRef
Diniz BS, Teixeira AL (2011) Brain-derived neurotrophic factor and Alzheimer’s disease: physiopathology and beyond. NeuroMol Med 13:217–222CrossRef
Ekladious ST, El Sayed NS (2019) Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress. Behav Pharmacol 30(1):5–15PubMedCrossRef
El-Sahar AE, Shiha NA, El Sayed NS, Ahmed LA (2021) Alogliptin attenuates lipopolysaccharide-induced neuroinflammation in mice through modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 signaling pathways. Int J Neuropsychopharmacol 24(2):158–169PubMedCrossRef
Esposito M, Sherr GL (2019) Epigenetic modifications in Alzheimer’s neuropathology and therapeutics. Front Neurosci 13:449570CrossRef
Estfanous S, Daily KP, Eltobgy M, Deems NP, Anne MN, Krause K, Badr A, Hamilton K, Carafice C, Hegazi A (2021) Elevated expression of MiR-17 in microglia of Alzheimer’s disease patients abrogates autophagy-mediated amyloid-β degradation. Front Immunol 12:705581PubMedPubMedCentralCrossRef
Feng Y, Wang X (2012) Antioxidant therapies for Alzheimer’s disease. Oxidat Med Cell Long 2012:1–17CrossRef
Folch J, Petrov D, Ettcheto M, Abad S, Sánchez-López E, García ML, Olloquequi J, Beas-Zarate C, Auladell C, Camins A (2016) Current research therapeutic strategies for Alzheimer’s disease treatment. Neural Plast 2016:1–15CrossRef
Folke J, Pakkenberg B, Brudek T (2019) Impaired Wnt signaling in the prefrontal cortex of Alzheimer’s disease. Mol Neurobiol 56:873–891PubMedCrossRef
Fouad IA, Sharaf NM, Abdelghany RM, El Sayed NSED (2018) Neuromodulatory effect of thymoquinone in attenuating glutamate-mediated neurotoxicity targeting the amyloidogenic and apoptotic pathways. Front Neurol 9:236PubMedCrossRef
Freude S, Schilbach K, Schubert M (2009) The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer’s disease: from model organisms to human disease. Curr Alzheimer Res 6(3):213–223PubMedCrossRef
Gabbouj S, Ryhänen S, Marttinen M, Wittrahm R, Takalo M, Kemppainen S, Martiskainen H, Tanila H, Haapasalo A, Hiltunen M (2019) Altered insulin signaling in Alzheimer’s disease brain–special emphasis on PI3K-Akt pathway. Front Neurosci 13:629PubMedCrossRef
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140(6):918–934PubMedCrossRef
Hao R, Song X, Li F, Tan X, Sun-Waterhouse D, Li D (2020) Caffeic acid phenethyl ester reversed cadmium-induced cell death in hippocampus and cortex and subsequent cognitive disorders in mice: involvements of AMPK/SIRT1 pathway and amyloid-tau-neuroinflammation axis. Food Chem Toxicol 144:111636PubMedCrossRef
Hasanabadi AJ, Beirami E, Kamaei M, Esfahani DE (2024) Effect of imipramine on memory, adult neurogenesis, neuroinflammation, and mitochondrial biogenesis in a rat model of alzheimer’s disease. Exp Gerontol 194:112517PubMedCrossRef
Hindam MO, Ahmed LA, Sayed NSE, Khattab M, Sallam NA (2024) Repositioning of baricitinib for management of memory impairment in ovariectomized/d-galactose treated rats: a potential role of JAK2/STAT3-PI3K/AKT/mTOR signaling pathway. Life Sci: 122838
Hu M, Wang H, Hu M, Long Y, Miao M-X, Li J-C, Wang X-B, Kong L-Y, Hong H (2014) Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. Neuropharmacology 79:707–714PubMedCrossRef
Huang C, Ma R, Sun S, Wei G, Fang Y, Liu R, Li G (2008) JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. J Neuroimmunol 204(1–2):118–125PubMedCrossRef
Huang M, Liang Y, Chen H, Xu B, Chai C, Xing P (2018) The role of fluoxetine in activating Wnt/β-catenin signaling and repressing β-amyloid production in an Alzheimer mouse model. Front Aging Neurosci 10:164PubMedCrossRef
Ibrahim WW, Abdel Rasheed NO (2022) Diapocynin neuroprotective effects in 3-nitropropionic acid Huntington’s disease model in rats: emphasis on Sirt1/Nrf2 signaling pathway. Inflammopharmacology 30(5):1745–1758PubMedCrossRef
Ibrahim WW, Abdelkader NF, Ismail HM, Khattab MM (2019) Escitalopram ameliorates cognitive impairment in d-galactose-injected ovariectomized rats: modulation of JNK, GSK-3β, and ERK signalling pathways. Sci Rep 9(1):10056PubMedCrossRef
Ibrahim WW, Ismail HM, Khattab MM, Abdelkader NF (2020) Cognitive enhancing effect of diapocynin in d-galactose-ovariectomy-induced Alzheimer’s-like disease in rats: role of ERK, GSK-3β, and JNK signaling. Toxicol Appl Pharmacol 398:115028PubMedCrossRef
Ibrahim M, Haleem M, AbdelWahab S, Abdel-Aziz A (2021) Sildenafil ameliorates Alzheimer disease via the modulation of vascular endothelial growth factor and vascular cell adhesion molecule-1 in rats. Hum Exp Toxicol 40(4):596–607PubMedCrossRef
Ibrahim WW, Kamel AS, Wahid A, Abdelkader NF (2022) Dapagliflozin as an autophagic enhancer via LKB1/AMPK/SIRT1 pathway in ovariectomized/d-galactose Alzheimer’s rat model. Inflammopharmacology 30(6):2505–2520PubMedCrossRef
Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM-Y, Trojanowski JQ (2012) Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain 135(3):807–818PubMedCrossRef
Javadpour P, Askari S, Rashidi FS, Dargahi L, Ahmadiani A, Ghasemi R (2021) Imipramine alleviates memory impairment and hippocampal apoptosis in STZ-induced sporadic Alzheimer’s rat model: possible contribution of MAPKs and insulin signaling. Behav Brain Res 408:113260PubMedCrossRef
Jia L, Piña-Crespo J, Li Y (2019) Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease. Mol Brain 12:1–11CrossRef
Jiang Q, Heneka M, Landreth GE (2008) The role of peroxisome proliferator-activated receptor-γ PPARγ) in Alzheimer’s disease: therapeutic implications. CNS Drugs 22:1–14PubMedCrossRef
Jin Y, Sun LH, Yang W, Cui RJ, Xu SB (2019) The role of BDNF in the neuroimmune axis regulation of mood disorders. Front Neurol 10:515PubMedCrossRef
Kamel AS, Abdelkader NF, Abd El-Rahman SS, Emara M, Zaki HF, Khattab MM (2018) Stimulation of ACE2/ANG (1–7)/Mas axis by diminazene ameliorates Alzheimer’s disease in the d-galactose-ovariectomized rat model: role of PI3K/Akt pathway. Mol Neurobiol 55:8188–8202PubMedCrossRef
Kang C (2024) Donanemab: first approval. Drugs: 1–6
Kaur B, Singh N, Jaggi AS (2009) Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fund Clin Pharmacol 23(5):557–566CrossRef
Khalifa M, Safar MM, Abdelsalam RM, Zaki HF (2020) Telmisartan protects against aluminum-induced Alzheimer-like pathological changes in rats. Neurotox Res 37:275–285PubMedCrossRef
Khamies SM, El-Yamany MF, Ibrahim SM (2024) Canagliflozin mitigated cognitive impairment in streptozotocin-induced sporadic Alzheimer’s disease in mice: role of AMPK/SIRT-1 signaling pathway in modulating neuroinflammation. J Neuroimmune Pharmacol 19(1):39PubMedCrossRef
Kim M-H, Hong S-H, Lee M-K (2013) Insulin receptor-overexpressing β-cells ameliorate hyperglycemia in diabetic rats through Wnt signaling activation. PLoS One 8(7):e67802PubMedCrossRef
Kitagishi Y, Nakanishi A, Ogura Y, Matsuda S (2014) Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer’s disease. Alzheimer’s Res Ther 6:1–7CrossRef
Kosaraju J, Murthy V, Khatwal RB, Dubala A, Chinni S, Muthureddy Nataraj SK, Basavan D (2013) Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer’s disease. J Pharm Pharmacol 65(12):1773–1784PubMedCrossRef
Krishna V, Nayak V, Pandey AK, Sunny SV, Bairy K (2021) Chronic treatment with escitalopram reversed scopolamine-induced memory impairment by enhancing cholinergic activity in wistar albino rats. Res J Pharm Technol 14(4):1887–1892CrossRef
Kumar A, Singh A (2015) A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions. Front Pharmacol 6:206PubMedCrossRef
Langa K, Kabeto M, Weir D (2009) 2010 Alzheimer’s disease facts and figures
Lee H-J, Choi H-J, Jeong YJ, Na Y-H, Hong JT, Han JT, Hoe H-S, Lim K-H (2024). "Developing theragnostics for Alzheimer's disease: Insights from cancer treatment. Int J Biol Macromol: 131925
Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179(2):312–339PubMedCrossRef
Long Z, Zheng M, Zhao L, Xie P, Song C, Chu Y, Song W, He G (2013) Valproic acid attenuates neuronal loss in the brain of APP/PS1 double transgenic Alzheimer’s disease mice model. Curr Alzheimer Res 10(3):261–269PubMedCrossRef
Lu J, Wu D-M, Zheng Y-L, Hu B, Zhang Z-F, Ye Q, Liu C-M, Shan Q, Wang Y-J (2010) Ursolic acid attenuates d-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-κB pathway activation. Cereb Cortex 20(11):2540–2548PubMedCrossRef
Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 24(1):1–23PubMedCrossRef
Mansour HM, Fawzy HM, El-Khatib AS, Khattab MM (2021a) Inhibition of mitochondrial pyruvate carrier 1 by lapatinib ditosylate mitigates Alzheimer’s-like disease in d-galactose/ovariectomized rats. Neurochem Int 150:105178PubMedCrossRef
Mansour HM, Fawzy HM, El-Khatib AS, Khattab MM (2021b) Lapatinib ditosylate rescues memory impairment in d-galactose/ovariectomized rats: potential repositioning of an anti-cancer drug for the treatment of Alzheimer’s disease. Exp Neurol 341:113697PubMedCrossRef
Mansour HM, Fawzy HM, El-Khatib AS, Khattab MM (2022) Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer’s disease. Neural Regen Res 17(9):1913PubMedPubMedCentralCrossRef
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer’s disease. Nat Rev Dis Primers 1(1):1–18CrossRef
McClean PL, Hölscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology 76:57–67PubMedCrossRef
Messiha BA, Ali MR, Khattab MM, Abo-Youssef AM (2020) Perindopril ameliorates experimental Alzheimer’s disease progression: role of amyloid β degradation, central estrogen receptor and hyperlipidemic-lipid raft signaling. Inflammopharmacology 28:1343–1364PubMedCrossRef
Min S-W, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, Mok SA (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21(10):1154–1162PubMedPubMedCentralCrossRef
Mohamed MAE, Abdel-Rahman RF, Mahmoud SS, Khattab MM, Safar MM (2020) Metformin and trimetazidine ameliorate diabetes-induced cognitive impediment in status epileptic rats. Epilepsy Behav 104:106893PubMedCrossRef
Mohammadpour JD, Hosseinmardi N, Janahmadi M, Fathollahi Y, Motamedi F, Rohampour K (2015) Non-selective NSAIDs improve the amyloid-β-mediated suppression of memory and synaptic plasticity. Pharmacol Biochem Behav 132:33–41CrossRef
Moustafa PE, Abdelkader NF, El Awdan SA, El-Shabrawy OA, Zaki HF (2018) Extracellular matrix remodeling and modulation of inflammation and oxidative stress by sulforaphane in experimental diabetic peripheral neuropathy. Inflammation 41:1460–1476PubMedCrossRef
Muneeb M, Mansou SM, Saleh S, Mohammed RA (2022) Vitamin D and rosuvastatin alleviate type-II diabetes-induced cognitive dysfunction by modulating neuroinflammation and canonical/noncanonical Wnt/β-catenin signaling. PLoS One 17(11):e0277457PubMedPubMedCentralCrossRef
Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W (2014) Insulin resistance, neuroinflammation, and Alzheimer’s disease. Rev Neurosci 25(4):509–525PubMedCrossRef
Nishiki S, Hato F, Kamata N, Sakamoto E, Hasegawa T, Kimura-Eto A, Hino M, Kitagawa S (2004) Selective activation of STAT3 in human monocytes stimulated by G-CSF: implication in inhibition of LPS-induced TNF-α production. Am J Physiol Cell Physiol 286(6):C1302–C1311PubMedCrossRef
Noble EE, Hsu TM, Kanoski SE (2017) Gut to brain dysbiosis: mechanisms linking western diet consumption, the microbiome, and cognitive impairment. Front Behav Neurosci 9
Owona BA, Zug C, Schluesener HJ, Zhang Z-Y (2019) Amelioration of behavioral impairments and neuropathology by antiepileptic drug topiramate in a transgenic Alzheimer’s disease model mice, APP/PS1. Int J Mol Sci 20(12):3003PubMedPubMedCentralCrossRef
Paladugu L, Gharaibeh A, Kolli N, Learman C, Hall TC, Li L, Rossignol J, Maiti P, Dunbar GL (2021) Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer’s disease. Int J Mol Sci 22(2):860PubMedPubMedCentralCrossRef
Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM (1987) Monoaminergic innervation of the frontal and temporal lobes in Alzheimer’s disease. Brain Res 401(2):231–238PubMedCrossRef
Pilipenko V, Narbute K, Pupure J, Langrate IK, Muceniece R, Kluša V (2020) Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer’s disease. Eur J Pharmacol 881:173290PubMedCrossRef
Plum L, Schubert M, Brüning JC (2005) The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 16(2):59–65PubMedCrossRef
Price TO, Farr SA, Niehoff ML, Ercal N, Morley JE, Shah GN (2015) Protective effect of topiramate on hyperglycemia-induced cerebral oxidative stress, pericyte loss and learning behavior in diabetic mice. Int Lib Diabet Metab 1(1):6
Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281(31):21745–21754PubMedCrossRef
Qu Z, Sun J, Zhang W, Yu J, Zhuang C (2020) Transcription factor NRF2 as a promising therapeutic target for Alzheimer’s disease. Free Radical Biol Med 159:87–102CrossRef
Ramirez MJ, Lai MK, Tordera RM, Francis PT (2014) Serotonergic therapies for cognitive symptoms in Alzheimer’s disease: rationale and current status. Drugs 74:729–736PubMedCrossRef
Rani A, Neha, Sodhi RK, Kaur A (2015) Protective effect of a calcium channel blocker “diltiazem” on aluminum chloride-induced dementia in mice. Naunyn-Schmiedeb Arch Pharmacol 388: 1151–1161
Rawdin B, Mellon S, Dhabhar F, Epel E, Puterman E, Su Y, Burke H, Reus V, Rosser R, Hamilton S (2013) Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun 31:143–152PubMedCrossRef
Razay G, Vreugdenhil A, Wilcock G (2007) The metabolic syndrome and Alzheimer disease. Arch Neurol 64(1):93–96PubMedCrossRef
Reyes JF, Reynolds MR, Horowitz PM, Fu Y, Guillozet-Bongaarts AL, Berry R, Binder LI (2008) A possible link between astrocyte activation and tau nitration in Alzheimer’s disease. Neurobiol Dis 31(2):198–208PubMedPubMedCentralCrossRef
Reynolds MR, Lukas TJ, Berry RW, Binder LI (2006) Peroxynitrite-mediated τ modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms. Biochemistry 45(13):4314–4326PubMedCrossRef
Riederer IM, Schiffrin M, Kövari E, Bouras C, Riederer BM (2009) Ubiquitination and cysteine nitrosylation during aging and Alzheimer’s disease. Brain Res Bull 80(4–5):233–241PubMedCrossRef
Rodríguez JJ, Noristani HN, Verkhratsky A (2012) The serotonergic system in ageing and Alzheimer’s disease. Prog Neurobiol 99(1):15–41PubMedCrossRef
Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer’s disease, role of cytokines. Sci World J 2012:1CrossRef
Salem MA, Budzyńska B, Kowalczyk J, El Sayed NS, Mansour SM (2021) Tadalafil and bergapten mitigate streptozotocin-induced sporadic Alzheimer’s disease in mice via modulating neuroinflammation, PI3K/Akt, Wnt/β-catenin, AMPK/mTOR signaling pathways. Toxicol Appl Pharmacol 429:115697PubMedCrossRef
Samman WA, Selim SM, El Fayoumi HM, El-Sayed NM, Mehanna ET, Hazem RM (2023) Dapagliflozin ameliorates cognitive impairment in aluminum-chloride-induced Alzheimer’s disease via modulation of AMPK/mTOR, oxidative stress and glucose metabolism. Pharmaceuticals 16(5):753PubMedPubMedCentralCrossRef
Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu G-Q, Palop JJ (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci 109(42):E2895–E2903PubMedPubMedCentralCrossRef
Sayed AS, El Sayed NSED (2016) Co-administration of 3-acetyl-11-keto-beta-boswellic acid potentiates the protective effect of celecoxib in lipopolysaccharide-induced cognitive impairment in mice: possible implication of anti-inflammatory and antiglutamatergic pathways. J Mol Neurosci 59:58–67PubMedCrossRef
Shindo T, Takasaki K, Uchida K, Onimura R, Kubota K, Uchida N, Irie K, Katsurabayashi S, Mishima K, Nishimura R (2012) Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer’s disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull 35(12):2141–2147PubMedCrossRef
Sorial ME, El Sayed NSED (2017) Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer’s disease mouse model: possible involvement of the cholinergic system. Naunyn Schmiedeb Arch Pharmacol 390:581–593CrossRef
Tamagno E, Guglielmotto M, Monteleone D, Vercelli A, Tabaton M (2012) Transcriptional and post-transcriptional regulation of β-secretase. IUBMB Life 64(12):943–950PubMedCrossRef
Tan M-S, Yu J-T, Jiang T, Zhu X-C, Tan L (2013) The NLRP3 inflammasome in Alzheimer’s disease. Mol Neurobiol 48:875–882PubMedCrossRef
Tang K-K, Liu X-Y, Wang Z-Y, Qu K-C, Fan R-F (2019) Trehalose alleviates cadmium-induced brain damage by ameliorating oxidative stress, autophagy inhibition, and apoptosis. Metallomics 11(12):2043–2051PubMedCrossRef
Teixeira JP, de Castro AA, Soares FV, da Cunha EF, Ramalho TC (2019) Future therapeutic perspectives into the Alzheimer’s disease targeting the oxidative stress hypothesis. Molecules 24(23):4410PubMedPubMedCentralCrossRef
Tian A, Li W, Zai Q, Li H, Zhang RW (2020) 3-N-Butyphthalide improves learning and memory in rats with vascular cognitive impairment by activating the SIRT1/BDNF pathway. Mol Med Rep 22(1):525–533PubMedPubMedCentralCrossRef
Tota S, Kamat PK, Awasthi H, Singh N, Raghubir R, Nath C, Hanif K (2009) Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 199(2):235–240PubMedCrossRef
Tracy TE, Gan L (2017) Acetylated tau in Alzheimer’s disease: An instigator of synaptic dysfunction underlying memory loss: Increased levels of acetylated tau blocks the postsynaptic signaling required for plasticity and promotes memory deficits associated with tauopathy. BioEssays 39(4):1600224CrossRef
Turenne GA, Price BD (2001) Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53’s transcriptional activity. BMC Cell Biol 2(1):1–9CrossRef
Varadharajan A, Davis AD, Ghosh A, Jagtap T, Xavier A, Menon AJ, Roy D, Gandhi S, Gregor T (2023) Guidelines for pharmacotherapy in Alzheimer’s disease–a primer on FDA-approved drugs. J Neurosci Rural Pract 14(4):566PubMedPubMedCentralCrossRef
Vasconcelos AR, Dos Santos NB, Scavone C, Munhoz CD (2019) Nrf2/ARE pathway modulation by dietary energy regulation in neurological disorders. Front Pharmacol 10:428667CrossRef
Villar J, Cabrera NE, Valladares F, Casula M, Flores C, Blanch L, Quilez ME, Santana-Rodríguez N, Kacmarek RM, Slutsky AS (2011) Activation of the Wnt/β-catenin signaling pathway by mechanical ventilation is associated with ventilator-induced pulmonary fibrosis in healthy lungs. PLoS One 6(9):e23914PubMedPubMedCentralCrossRef
Xie L, Helmerhorst E, Plewright B, Van Bronswijk W, Martins R (2002) Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22(RC221):1–5
Xu T, Liu J, Li X-R, Yu Y, Luo X, Zheng X, Cheng Y, Yu P-Q, Liu Y (2021) The mTOR/NF-κB pathway mediates neuroinflammation and synaptic plasticity in diabetic encephalopathy. Mol Neurobiol 58:3848–3862PubMedCrossRef
Xuan A-G, Pan X-B, Wei P, Ji W-D, Zhang W-J, Liu J-H, Hong L-P, Chen W-L, Long D-H (2015) Valproic acid alleviates memory deficits and attenuates amyloid-β deposition in transgenic mouse model of Alzheimer’s disease. Mol Neurobiol 51:300–312PubMedCrossRef
Yang W-N, Han H, Hu X-D, Feng G-F, Qian Y-H (2013) The effects of perindopril on cognitive impairment induced by d-galactose and aluminum trichloride via inhibition of acetylcholinesterase activity and oxidative stress. Pharmacol Biochem Behav 114:31–36PubMedCrossRef
Yao W, Lin S, Su J, Cao Q, Chen Y, Chen J, Zhang Z, Hashimoto K, Qi Q, Zhang J-C (2021) Activation of BDNF by transcription factor Nrf2 contributes to antidepressant-like actions in rodents. Transl Psychiatry 11(1):140PubMedCrossRef
Ye F, Wu A (2021) The protective mechanism of SIRT1 in the regulation of mitochondrial biogenesis and mitochondrial autophagy in Alzheimer’s disease. J Alzheimers Dis 82(1):149–157PubMedCrossRef
Yerraguravagari B, Penchikala NP, Kolusu AS, Ganesh GS, Konduri P, Nemmani KV, Samudrala PK (2024) Montelukast ameliorates scopolamine-induced alzheimer’s disease: role on cholinergic neurotransmission, antioxidant defence system, neuroinflammation and expression of BDNF. CNS Neurol Disord Drug Targets (Form Curr Drug Targets CNS Neurol Dis) 23(8):1040–1055CrossRef
Yossef RR, Al-Yamany MF, Saad MA, El-Sahar AE (2020) Neuroprotective effects of vildagliptin on drug induced Alzheimer’s disease in rats with metabolic syndrome: role of hippocampal klotho and AKT signaling pathways. Eur J Pharmacol 889:173612PubMedCrossRef
Zhang J, Guo J, Zhao X, Chen Z, Wang G, Liu A, Wang Q, Zhou W, Xu Y, Wang C (2013) Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 250:230–237PubMedCrossRef
Zhang CT, Lin JR, Wu F, Ghosh A, Tang SS, Hu M, Long Y, Sun HB, Hong H (2016) Montelukast ameliorates streptozotocin-induced cognitive impairment and neurotoxicity in mice. Neurotoxicology 57:214–222PubMedCrossRef
Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, Cao Y, Li H (2021) Interaction between Aβ and tau in the pathogenesis of Alzheimer’s disease. Int J Biol Sci 17(9):2181PubMedCrossRef
Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci 24(49):11120–11126PubMedCrossRef
Zhao Y, Hill JM, Bhattacharjee S, Percy ME, Pogue AI, Lukiw WJ (2014) Aluminum-induced amyloidogenesis and impairment in the clearance of amyloid peptides from the central nervous system in Alzheimer’s disease. Front Neurol 5:167PubMedCrossRef
Zhou CN, Chao FL, Zhang Y, Jiang L, Zhang L, Fan JH, Wu YX, Dou XY, Tang Y (2019) Fluoxetine delays the cognitive function decline and synaptic changes in a transgenic mouse model of early Alzheimer’s disease. J Compar Neurol 527(8):1378–1387CrossRef
Metadata
Title
Drugs repurposing in the experimental models of Alzheimer’s disease
Authors
Sheer A. Joodi
Weam W. Ibrahim
Mahmoud M. Khattab
Publication date
03-01-2025
Publisher
Springer International Publishing
Published in
Inflammopharmacology
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-024-01608-7